Zobrazit v EDS

Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with Ticagrelor: Pharmacodynamic data from the POMPEII study

Uloženo v:
Podrobná bibliografie
Název: Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with Ticagrelor: Pharmacodynamic data from the POMPEII study
Autoři: Giuseppe Gargiulo, Plinio Cirillo, Luca Sperandeo, Imma Forzano, Domenico Simone Castiello, Domenico Florimonte, Fiorenzo Simonetti, Roberta Paolillo, Lina Manzi, Alessandra Spinelli, Carmen Anna Maria Spaccarotella, Raffaele Piccolo, Luigi Di Serafino, Anna Franzone, Piera Capranzano, Marco Valgimigli, Giovanni Esposito
Zdroj: International Journal of Cardiology: Heart & Vasculature, Vol 50, Iss , Pp 101344- (2024)
Informace o vydavateli: Elsevier, 2024.
Rok vydání: 2024
Sbírka: LCC:Diseases of the circulatory (Cardiovascular) system
Témata: STEMI, Primary PCI, Cangrelor, Pharmacodynamic assessment, Platelet inhibition, Ticagrelor pretreatment, Diseases of the circulatory (Cardiovascular) system, RC666-701
Popis: Background: There are limited data to assess pharmacodynamic (PD) profiles of patients with STEMI undergoing primary percutaneous coronary intervention (PCI) and receiving cangrelor after pretreatment with ticagrelor. Methods: The PharmacOdynaMic effects of cangrelor in PatiEnts wIth acute or chronIc coronary syndrome undergoing percutaneous coronary intervention (POMPEII) registry (NCT04790032) is a prospective study conducted at Federico II University of Naples enrolling all patients undergoing PCI receiving cangrelor at operator’s discretion. PD assessments were performed with 3 assays: (1) the gold standard light transmittance aggregometry (LTA) (20- and 5-μM adenosine diphosphate [ADP] stimuli); (2) VerifyNow P2Y12-test; (3) Multiplate electrode aggregometry (MEA), ADP-test. Results: We analyzed 13 STEMI patients pretreated with ticagrelor within 1 h at the time they underwent primary PCI receiving cangrelor. All patients showed low maximal platelet aggregation at 30-minute during cangrelor infusion, as well as at 3 h and 4–6 h (corresponding to 1 h and 2–4 h after stopping cangrelor infusion) with no cases of high residual platelet reactivity. These results were consistent with all assays. Conclusions: PD data show that in contemporary real-world STEMI patients pretreated within 1 h with ticagrelor undergoing primary PCI, adding cangrelor resulted in fast and potent platelet inhibition, thus suggesting that cangrelor may bridge the gap until ticagrelor reaches its effect.
Druh dokumentu: article
Popis souboru: electronic resource
Jazyk: English
ISSN: 2352-9067
Relation: http://www.sciencedirect.com/science/article/pii/S2352906724000101; https://doaj.org/toc/2352-9067
DOI: 10.1016/j.ijcha.2024.101344
Přístupová URL adresa: https://doaj.org/article/165157f62580481a8b26660fa57779c6
Přístupové číslo: edsdoj.165157f62580481a8b26660fa57779c6
Databáze: Directory of Open Access Journals
Popis
Abstrakt:Background: There are limited data to assess pharmacodynamic (PD) profiles of patients with STEMI undergoing primary percutaneous coronary intervention (PCI) and receiving cangrelor after pretreatment with ticagrelor. Methods: The PharmacOdynaMic effects of cangrelor in PatiEnts wIth acute or chronIc coronary syndrome undergoing percutaneous coronary intervention (POMPEII) registry (NCT04790032) is a prospective study conducted at Federico II University of Naples enrolling all patients undergoing PCI receiving cangrelor at operator’s discretion. PD assessments were performed with 3 assays: (1) the gold standard light transmittance aggregometry (LTA) (20- and 5-μM adenosine diphosphate [ADP] stimuli); (2) VerifyNow P2Y12-test; (3) Multiplate electrode aggregometry (MEA), ADP-test. Results: We analyzed 13 STEMI patients pretreated with ticagrelor within 1 h at the time they underwent primary PCI receiving cangrelor. All patients showed low maximal platelet aggregation at 30-minute during cangrelor infusion, as well as at 3 h and 4–6 h (corresponding to 1 h and 2–4 h after stopping cangrelor infusion) with no cases of high residual platelet reactivity. These results were consistent with all assays. Conclusions: PD data show that in contemporary real-world STEMI patients pretreated within 1 h with ticagrelor undergoing primary PCI, adding cangrelor resulted in fast and potent platelet inhibition, thus suggesting that cangrelor may bridge the gap until ticagrelor reaches its effect.
ISSN:23529067
DOI:10.1016/j.ijcha.2024.101344